Dolutegravir: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Cases RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)−15%

Mortality (1)−202%

Cases (1)−20%

RCTs (1)−202%

Prophylaxis (1)−14%

Late (1)−202%

00.511.5+

← Dolutegravir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Dolutegravir COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.32death1/460/47

Late treatment−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

Verburgh−14%1.14 · 0.75–1.72death/hosp.626 (n)881 (n)

Prophylaxis−14%1.14 · 0.76–1.69626 (n)881 (n)14% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.54

All studies−15%1.15 · 0.78–1.711/6720/92815% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4900.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.321/460/47

Late treatment−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.32death1/460/47

Late treatment−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

Verburgh−14%1.14 · 0.75–1.72death/hosp.626 (n)881 (n)

Prophylaxis−14%1.14 · 0.76–1.69626 (n)881 (n)14% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.54

All studies−15%1.15 · 0.78–1.711/6720/92815% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4900.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 case results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Verburgh−20%1.20 · 0.38–3.85cases45 (n)111 (n)

Prophylaxis−20%1.20 · 0.41–3.5845 (n)111 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.75

All studies−20%1.20 · 0.41–3.5845 (n)111 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7500.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.32death1/460/47

Late treatment−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.321/460/47

Late treatment−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.32death1/460/47

Late treatment−202%3.02 · 0.13–72.321/460/47202% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.5

Verburgh−14%1.14 · 0.75–1.72death/hosp.626 (n)881 (n)

Prophylaxis−14%1.14 · 0.76–1.69626 (n)881 (n)14% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.54

All studies−15%1.15 · 0.78–1.711/6720/92815% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4900.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →

c19early.org

October 2026

Dolutegravir COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Abbaspou.. (DB RCT)−202%3.02 · 0.13–72.32death1/460/47 Abbaspou.. (DB RCT)5%0.95 · 0.52–1.75oxygen14/4615/47 Verburgh−14%1.14 · 0.75–1.72death/hosp.626 (n)881 (n) Verburgh−20%1.20 · 0.38–3.85cases45 (n)111 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Dolutegravir
reduces riskDolutegravir
increases risk →